Short description

LumiSTAR is developing a pipeline of innovative cell therapies based on induced pluripotent stem cell (iPSC) technology. These therapies have the potential to revolutionize the treatment of a wide range of diseases, including neurodegenerative diseases such as Parkinson's and Alzheimer's, kidney failure and cancer. Other than cell therapy, the company also equipped with iPSC and bioimaging-based high throughput drug screening platform to develop new drugs. The platform uses iPSC to create disease models for drug discovery and screening, allowing for more accurate and efficient identification of potential drug candidates. 

The bioimaging-based drug discovery platform of the company has demonstrated remarkable effectiveness in the fight against renal and pulmonary fibrosis. In less than 2 years, the company has identified 2 promising drug candidates for the conditions by drug repurposing, and these candidates have shown potential in animal experiments. The fact that there is currently only 1 FDA-approved drug for renal fibrosis in the world underscores the significance of the company's findings. These results offer hope for improved treatment options for fibrosis patients and demonstrate the potential of the company's platform to discover new drugs efficiently and effectively.